Cortexyme (NASDAQ:CRTX) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Cortexyme, Inc. (NASDAQ:CRTX)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.19 and traded as high as $3.66. Cortexyme shares last traded at $3.55, with a volume of 2,857,492 shares changing hands.

Cortexyme Price Performance

The company has a market cap of $107.04 million, a P/E ratio of -1.20 and a beta of 1.40. The stock has a 50-day moving average of $3.09 and a 200 day moving average of $2.19.

Cortexyme Company Profile

Cortexyme, Inc is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.

The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity.